1428787-48-7

Upstream product

• 1449763-32-9 phenyl 3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperdine-1-yl)propoxy)quinolin-4-yloxy)phenylcarbamate 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 1290538-61-2 3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperidin-1-yl)propoxy]quinolin-4-yloxy}phenylamine 
• 1436418-01-7 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinoline 
• 1436417-99-0 4-chloro-6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)-quinoline 
• 1436417-98-9 6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)-quinolin-4-ol 
• 1394166-09-6 6-methyloxy-7-(4-(3-chloropropoxy))-4-4-hydroxyquinoline 
• 1449763-02-3 1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 
• 1449763-35-2 N¹-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperidin-1-yl)-propoxy)quinolin-4-yloxy)phenyl)semicarbazide 
• 100-52-7 benzaldehyde 
• 1160707-44-7 1-[4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl]ethan-1-one 
• 58113-30-7 4-(3-chloropropoxy)-3-methoxyacetophenone 

Relevant academic research and scientific papers

NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS

The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors

A novel series of N1-(3-fluoro-4-(6,7-disubstituted-quinolin-4- yloxy)phenyl)-N4-arylidenesemicarbazide derivatives were synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against A549, HT-29, MKN-45 and MDA-MB-231 cancer cell lines in vitro. Several potent compounds were further evaluated against three other cancer cell lines (U87MG, NCI-H460 and SMMC7721). Most of compounds tested exhibited moderate to excellent activity. The studies of SARs identified the most promising compound 28 (c-Met IC50 = 1.4 nM) as a c-Met kinase inhibitor. In this study, a promising compound 28 was identified, which displayed 2.1-, 3.3-, 48.4- and 3.6-fold increase against A549, HT-29, U87MG and NCI-H460 cell lines, respectively, compared with that of Foretinib.